RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors.

Area of Science:

• Biochemistry
• Computational Biology
• Drug Discovery

Background:

• 90 kDa ribosomal S6 serine/threonine kinases (RSK1-4) are key downstream effectors in the MAPK pathway, making them attractive targets for cancer therapy.
• Current research focuses on optimizing pan-RSK inhibitors, but isoform-specific targeting is needed due to distinct biological roles.

Purpose of the Study:

• To review and consolidate existing RSK models, highlighting isoform-specific structural differences.
• To evaluate computational methods for RSK inhibitor screening and development.
• To guide the design of next-generation, isoform-selective RSK inhibitors.

Main Methods:

• Examination of computational artifacts in molecular modeling, quantum mechanical calculations, molecular dynamics, and high-throughput screening.
• Analysis of structural variations among RSK isoforms using available crystal structures and homology modeling.
• Consolidation of existing RSK models and assessment of inhibition studies for selectivity.

Main Results:

• Significant variations exist between RSK structural models, offering opportunities for novel targeting strategies.
• Homology modeling and dynamic conformations can reveal new approaches for targeting RSK proteins.
• Current RSK modeling often generalizes findings across isoforms, underscoring the need for isoform-specific models.

Conclusions:

• Developing accurate, isoform-specific RSK models is critical for advancing selective inhibitor design.
• Leveraging subtle structural differences through computational methods will enable next-generation isoform-selective RSK inhibitors.
• Computational approaches are essential for overcoming challenges in RSK inhibitor development and achieving targeted cancer therapy.